Talphera

Talphera OCF Margin

The Operating Cash Flow Margin of Talphera (TLPH) as of Nov 6, 2026 is -40,585.71 %. In the previous year, Operating Cash Flow Margin was -2,686.94 % — a change of 1,410.48% (lower).

OCF Margin

-40,585.71 %

YoY

1,410.48%

Last updated:

Operating Cash Flow Margin of Talphera is 2025 -40,585.71 % . Operating Cash Flow Margin of Talphera was 2024 -2,686.94 % . It decreases by 1,410.48% lower compared to the previous year.

The Talphera OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-372.30 USD
Jan 1, 2018
-1,351.70 USD
Jan 1, 2019
-2,235.91 USD
Jan 1, 2020
-710.95 USD
Jan 1, 2021
-7,937.04 USD
Jan 1, 2022
-1,599.72 USD
Jan 1, 2023
-2,686.94 USD
Jan 1, 2025
-40,585.71 USD
The Talphera OCF Margin history
YEAROCF MarginYoY
-40,585.71 %+1,410.48%
-2,686.94 %+67.96%
-1,599.72 %-79.84%
-7,937.04 %+1,016.40%
-710.95 %-68.20%
-2,235.91 %+65.42%
-1,351.70 %+263.07%
-372.30 %+119.83%
-169.36 %+63.50%
-103.58 %-84.32%
-660.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

Operating Cash Flow Margin of Talphera is -40,585.71 % in 2025.

Operating Cash Flow Margin of Talphera changed from -2,686.94 % to -40,585.71 %, representing a 1,410.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Talphera since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Talphera with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Talphera

All Key Metrics — Talphera